Document is current
Any future updates will be listed below
-
Authors
Araujo, Daniel V. https://orcid.org/0000-0002-7013-5408
Uchoa, Bruno
Soto-Castillo, Juan José https://orcid.org/0000-0001-9630-4233
Furlan, Larissa L.
Oliva, Marc https://orcid.org/0000-0001-5352-8130
- License Information
-
More Information
Article History
Accepted: 3 May 2022
First Online: 10 June 2022
Declarations
:
: There was no funding required for this work.
: DVA: Advisory role for MSD. Honoraria from MSD, Pfizer, GSK, and Libbs. MO: Advisory role for Merck, Bristol-Myers Squibb. Honoraria from Bristol-Myers Squibb, MSD, Transgene and Merck. Research funding (Clinical Trials): Abbvie, Ayala Pharmaceuticals, MSD, AL Oncology, Debiopharm International, Merck, ISA Pharmaceuticals, Roche Pharmaceuticals. JJS, BU and LLF have no disclosures to report.
: Not applicable.
: Not applicable.
: All data generated or analysed during this study are included in this published article.
: Not applicable.
: Conceptualization: DVA and MO; methodology: DVA and MO; Investigation: BU, JJS and LLF; data curation: DVA, JJS and MO; writing—original draft: all authors; writing—review and editing: all authors; supervision: DVA and MO.
